Adjuvant Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous SCC

By News Health
4 weeks Ago

(MedPage Today) — CHICAGO — Adjuvant cemiplimab (Libtayo) significantly improved disease-free survival (DFS) compared with placebo in patients at high risk of recurrence of cutaneous squamous-cell carcinoma (SCC), a phase III randomized trial…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115862

Author :

Publish date : 2025-06-02 18:52:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Gender Differences With Low-Dose Minoxidil Side Effects

Ablation Still Best Option When Patient Has AF and Obesity

13 Cancers in One Blood Test — but 75% False Alarms

Parents face barriers to vaccinating children, says report

Could he really revolutionise US healthcare?

Polycystic ovary syndrome may be passed on via chemical tags on DNA